T-cell immunotherapy in cystic fibrosis: weighing the risk/reward.
about
IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosisModulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.Regulatory T-cell impairment in cystic fibrosis patients with chronic pseudomonas infection.Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis.Anti-bacterial antibody and T cell responses in bronchiectasis are differentially associated with lung colonization and disease.
P2860
T-cell immunotherapy in cystic fibrosis: weighing the risk/reward.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
T-cell immunotherapy in cystic fibrosis: weighing the risk/reward.
@en
T-cell immunotherapy in cystic fibrosis: weighing the risk/reward.
@nl
type
label
T-cell immunotherapy in cystic fibrosis: weighing the risk/reward.
@en
T-cell immunotherapy in cystic fibrosis: weighing the risk/reward.
@nl
prefLabel
T-cell immunotherapy in cystic fibrosis: weighing the risk/reward.
@en
T-cell immunotherapy in cystic fibrosis: weighing the risk/reward.
@nl
P2860
P1476
T-cell immunotherapy in cystic fibrosis: weighing the risk/reward.
@en
P2093
John F Alcorn
Keven M Robinson
P2860
P304
P356
10.1164/RCCM.201212-2201ED
P407
P577
2013-03-01T00:00:00Z